⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646321 | 0.63 | — | — | |
| SCHEMBL7898574 | 0.63 | — | — | |
| SCHEMBL10615408 | 0.59 | — | — | |
| SCHEMBL7648923 | 0.58 | — | — | |
| SCHEMBL11152437 | 0.56 | — | — | |
| SCHEMBL19532015 | 0.56 | — | — | |
| SCHEMBL12138622 | 0.56 | — | — | |
| SCHEMBL37030 | 0.56 | — | — | |
| SCHEMBL16585823 | 0.53 | — | — | |
| SCHEMBL11497448 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882059-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS INC (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | claimed |
| US-5824793-A | ACTIVATING A 3'-DEPROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE WITH TETRAZOLE AND REACTING WITH A 3'-PROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE; OXIDATION OF THE PHOSPHORUS; | LYNX THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | claimed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4694931-A1 | EXTRAHEPATIC DELIVERY OF DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-12357698-B1 | FUS proteolysis-targeting chimera, preparation method and applications thereof | SHANDONG NORMAL UNIVERSITY (CN) | 2025-07-15 | — | — | US | disclosed |
| CN-119842706-A | Nucleic acid for inhibiting expression of LPA in cells | 赛伦斯治疗有限责任公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119120476-A | Nucleic acid for inhibiting expression of LPA in cells | 赛伦斯治疗有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240327843-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| CN-118480073-A | Polymeric tandem dyes with linker groups | 索尼公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-0562014-A4 | — | — | 1994-02-23 | — | — | EP | disclosed |
| EP-0380559-B1 | OLIGONUCLEOTIDE FUNCTIONALIZING REAGENTS AND METHODS | CETUS ONCOLOGY CORP (US) | 1993-12-22 | — | — | EP | disclosed |
| EP-0562014-A1 | METHODS FOR LABELLING OLIGONUCLEOTIDES | ABBOTT LABORATORIES (US) | 1993-09-29 | — | — | EP | disclosed |
| EP-0315499-B1 | NUCLEOSIDE DERIVATIVES, PARTICULARLY OF 2'-DEOXYCYTIDINE, AND THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992010505-A1 | METHODS FOR LABELLING OLIGONUCLEOTIDES | ABBOTT LABORATORIES (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0380559-A1 | OLIGONUCLEOTIDE FUNCTIONALIZING REAGENTS AND METHODS. | CETUS CORP (US) | 1990-08-08 | — | — | EP | disclosed |
| US-4914210-A | Oligonucleotide functionalizing reagents | CETUS CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| WO-1989002931-A1 | OLIGONUCLEOTIDE FUNCTIONALIZING REAGENTS AND METHODS | CETUS CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |